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Summary
Objectives: The correlation between seroreactivity to Helicobacter pylori-specific antigens and
clinical outcomes in gastrointestinal disease remains unresolved. We investigated the anti-H.
pylori antibody profile in northeast Thai dyspeptic patients with gastrointestinal disease in order
to identify any H. pylori antigens that may be associated with an increased risk of gastrointestinal
disease.
Patients and methods: Eighty-nine H. pylori-infected dyspeptic patients (44 non-ulcer, 23 peptic
ulcer, 22 gastric cancer) were included in the study. Patients were considered to have H. pylori
infection when at least one invasive method (i.e., culture, rapid urease test, and histology on
biopsy specimens) and serological tests including a commercial ELISA (Pyloriset EIA-GIII) and a
commercial immunoblot (Helicoblot 2.1; Genelabs Diagnostics), were positive. In addition, the
sera of 20 H. pylori-infected blood donors and 10 H. pylori-non-infected blood donors were also
randomly collected and analyzed for H. pylori infection by ELISA and Helicoblot 2.1.
Results: Immunoreactive protein bands at 116-kDa, 89-kDa, 37-kDa, 35-kDa, 30-kDa, 19.5-kDa,
and the current infection marker for H. pylori-infected patients had average frequencies of
97.8%, 77.5%, 36.0%, 25.8%, 79.8%, 58.4%, and 69.7%, respectively. The immunoreactive patterns
obtained from the H. pylori-infected patients and H. pylori-infected blood donors were similar.
The antibodies to VacA and CagA antigens were not significantly different among the H. pylori-
infected gastroduodenal patient groups. The simultaneous presence of antibody to 19.5-kDa
antigen and absence of antibody to 35-kDa antigen was associated with an increased risk of gastric
cancer (p < 0.05). The immunoreactive band to 35-kDa antigen was found at significantly higher
levels in peptic ulcer patients, and the 37-kDa antigen was found at significantly higher levels in
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non-ulcer patients (both p < 0.05). Significantly low levels of antibodies to 23-kDa and 85-kDa
antigens were found associated with peptic ulcer ( p < 0.05).
Conclusions: We confirm that the universal presence of CagA and VacA in H. pylori-infected
patients in Thailand is independent of the gastroduodenal disease. The presence or absence of
antibodies to H. pylori-specific antigens may be useful as indirect markers in the screening of H.
pylori-infected patients, and may have specific protection roles in H. pylori-related gastroduo-
denal diseases.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Helicobacter pylori is accepted as an important pathogenic
factor in human non-ulcer dyspepsia, peptic ulcer dyspepsia,
and gastric carcinoma.1,2 The clinical outcome of H. pylori
infection shows marked variation, due mainly to diversity in
the strain, environmental factors, and host response.3,4 Since
clinical outcomes depend on both the characteristics of the
strain and the host response, the antibody response to H.
pylori could provide clues for predicting the severity of H.
pylori-associated diseases.5
The humoral immune response against H. pylori has,
however, been reported to show a high polymorphism, which
may reflect either an evolution of the immune response or an
antigenic shift of the infecting strain.6 This antibody poly-
morphism could be related to pathological status and thus
may serve as a biological predictor of the gastroduodenal
disease in the H. pylori-infected.
Many major surface-exposed or surface-secreted anti-
gens, such as the cytotoxin-associated protein (CagA), the
vacuolating cytotoxin protein (VacA), urease subunits (UreA
and UreB), heat-shock protein (HspA and HspB), flagellin
subunits, catalase, lipopolysaccharide, and several unde-
fined antigens, have been studied.7
The important putative virulence factors of H. pylori,
including CagA (a product of the cagA gene) and VacA (a
product of the vacA gene), have been considered to con-
tribute to the risk of developing different H. pylori-related
outcomes in Western countries.8,9 However, several studies
in Asia, including Thailand, have shown that the presence of
the cagA gene and the different types of vacA are not related
to clinical outcomes, as almost all H. pylori strains in Thai-
land are cagA-positive and of vacAs1 genotype.10 Thus, the
prevalence of these individual antigens (VacA and CagA) has
little or no value in predicting the clinical outcome in many
countries in Asia.11—15
It has been suggested that the low molecular weight
(19.5—35-kDa) proteins play an important role in the patho-
genesis of H. pylori-related disease.5,15,16 Furthermore, it
has been reported that the combination of the presence of
seroreactivity to 19.5-kDa antigen and the absence of ser-
oreactivity to 35-kDa antigen is associated with gastric can-
cer in Singapore.17 The simultaneous presence of CagA and
26.5-kDa antigen related to peptic ulcer has been reported in
Taiwan,11 and Shiesh et al. found a significant association
between the serological response to 19.5-kDa and 26.5-kDa
antigens and gastric cancer in Taiwan.14
The inconsistency of previous reports makes it necessary
to determine whether the association between the serolo-
gical response to H. pylori proteins and specific gastroduo-
denal diseases depends on geographic distribution, andwhether the antigens are related to the type of gastroduo-
denal disease. These may be useful as markers in screening
gastroduodenal diseases and in vaccine development.
The aim of this study was to investigate the anti-H. pylori
antibody profile by immunoblot assay (Helicoblot 2.1; HB 2.1)
in order to correlate the H. pylori antigens to the clinical
outcomes of gastroduodenal diseases in a Thai population.
Materials and methods
Patient population
One hundred and six dyspeptic patients who underwent
upper gastrointestinal endoscopy at Srinagarind Hospital,
Faculty of Medicine, Khon Kaen University, were randomly
included in this study. The dyspeptic patients were identi-
fied as having non-ulcer dyspepsia (NUD), peptic ulcer
dyspepsia (PUD), and gastric cancer (GCA) by the clinical
endoscopic doctor and pathologist. During endoscopy,
biopsy specimens were taken for the detection of H. pylori
by culture, rapid urease test (RUT), and histology. Blood
samples from each patient were collected in standard vials
as described below.
The subjects who had H. pylori infection according to our
criteria were comprised of 44 NUD, 23 PUD, and 22 GCA.
Seventeen subjects (10 NUD, 4 PUD, and 3 GCA) did not have
H. pylori infection according to our criteria. The patients
were 48 males and 58 females with an age range of 18 to 78
years (mean 42 years). Patients who had had antibiotic
therapy, as bismuth treatment, proton pump inhibitors, or
H2-blockers within the previous month were excluded.
The positive criteria for H. pylori infection were: a posi-
tive result for at least one of the invasive methods (i.e.,
culture, RUT, or histological examination) and positive
results by ELISA and Western immunoblot. In contrast, when
all invasive methods, the ELISA test, and the Western immu-
noblot were negative, patients were considered to be H.
pylori-non-infected.
Control population
A total of 30 consecutive blood donors, asymptomatic for
dyspepsia, attending the Srinagarind Hospital Blood Bank,
Khon Kaen University, were randomly included. Blood speci-
mens were subjected to ELISA and immunoblot (HB 2.1)
analysis.
The blood donors were determined to be in the infected
state when ELISA and Western immunoblot were positive,
whereas the non-infected state was determined when ELISA
and Western immunoblot were negative.
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Six gastric biopsy specimens (three each from the antrum and
the corpus) were taken from each patient for culture, RUT
(Pronto Dry test), and histological examination. Blood sam-
ples were taken, and sera were separated by centrifugation
and stored at  20 8C until use.
Culture
Culture was performed according to the method of Hazell
et al.,18 with modifications as previously described.10 Briefly,
each antral and corpus specimen was immediately placed
into transport medium and brought to the laboratory within
2 h, at 4 8C. Each biopsy specimen was homogenized sepa-
rately in 200 ml of normal saline solution and cultured on 7%
human blood agar (Difco, Detroit, MI, USA) containing the
supplement SR147 (5 mg/l trimethoprim, 10 mg/l vancomy-
cin, 5 mg/l amphotericin B, and 5 mg/l cefsulodin; OXOID,
Unipath Ltd, Basingstoke, UK). The plates were incubated at
37 8C under microaerophilic conditions (5% O2, 10% CO2, 85%
N2) and were examined after 4 and 7 days of incubation.
Characteristic colonies of H. pylori were confirmed by Gram
staining, oxidase, catalase, and urease tests.
Commercial rapid urease test (RUT, Pronto Dry
test)
The RUT was performed according to the manufacturer’s
instructions (Medical Instruments Corp., Solothurn, Switzer-
land) as previously described.10 Briefly, one antral and one
corpus specimen were directly inoculated onto the commer-
cial RUT agar gel. The results were observed and recorded
within 24 h. A positive result was indicated when the color
changed from yellow to pink.
Histological examination
One antral and one corpus biopsy were fixed in 10% buffered
formalin, processed, then embedded in paraffin. Four sec-
tions of 3- to 4-mm thick were stained with modified
Warthin—Starry stain for identification of H. pylori.19,20
The presence of spiral organisms on any of the slides was
considered positive for H. pylori.
ELISA and immunoblotting
Serum samples taken from the dyspeptic patients and blood
donors were assayed using a commercial ELISA kit (Pyloriset
EIA-GIII; Origon, Diagnostica, Espoo, Finland) and a commer-
cial immunoblot assay (Helicoblot 2.1 (HB 2.1); Genelabs
Diagnostics, Singapore). ELISA testing was performed accord-
ing to the manufacturer’s recommendations, as published in
a previous report.21
The immunoblot assay, HB 2.1, was used for the detection
of IgG antibodies to specific H. pylori proteins derived from
the lysates of an ulcerogenic strain and to a recombinant H.
pylori antigen as the current infection marker (CIM). The
assay was performed according to the manufacturer’s
instructions. Test strips contained different H. pylori anti-
gens, including the 116-kDa (CagA), 89-kDa (VacA), 37-kDa,35-kDa, 30-kDa, and 19.5-kDa antigens, and the CIM. The
determination of a positive H. pylori infection was made as
per the manufacturer’s instructions.
The presence of other immunoreactive bands was
assessed with a calibrating curve constructed by plotting
the distance of migration (in millimeters) of the immunor-
eactive bands obtained with the calibrating sera against the
molecular masses (in kDa) of the corresponding antigens.
Data analysis
The Chi-square and Fisher’s exact test were used to compare
the presence of specific antigens among patients with dif-
ferent gastroduodenal diseases. Logistic regression analysis
was used to determine the risk of gastric cancer. Statistical
significance was defined as p < 0.05.
Results
The frequency of the immunoreactive bands to CIM, 19.5-,
23-, 26-, 30- (UreA), 35-, 37-, 55-, 66-, 75-, 78-, 85-, 89-
(VacA), 93-, 110-, and 116- (CagA) kDa antigens among the H.
pylori-infected and H. pylori-non-infected patient groups,
and the H. pylori-infected and H. pylori-non-infected blood
donor groups, are shown in Table 1.
These band antigens were detected more frequently in
the H. pylori-infected patient group than in the H. pylori-
non-infected patient group (Table 1). No significant differ-
ence in these band antigens was detected in the H. pylori-
infected patient group compared to the H. pylori-infected
blood donor group, with the exceptions of the 37-kDa antigen
band, which was more frequently observed in the H. pylori-
infected blood donors than the H. pylori-infected patients
( p = 0.024), and the 89-kDa (VacA) antigen band, which was
more frequently observed in the H. pylori-infected patients
than the H. pylori-infected blood donors ( p = 0.039). The
immunoreactive bands were detected in the H. pylori-non-
infected patients and H. pylori-non-infected blood donors
less frequently than in theH. pylori-infected patients and the
H. pylori-infected blood donors.
As shown in Table 1, the manufacturer’s recommended
reference bands at 116-kDa, 89-kDa, 37-kDa, 35-kDa, 30-kDa,
19.5-kDa, and the CIM for H. pylori-infected patients had
average frequencies of 97.8%, 77.5%, 36.0%, 25.8%, 79.8%,
58.4%, and 69.7%, respectively.
Among the gastroduodenal diseases, seroreactivity to 35-
kDa was significantly found in PUD patients ( p = 0.02) and
that to 37-kDa was significantly found in NUD patients
( p = 0.002). The seroreactivity to 23- and 85-kDa bands
was found to be significantly low in PUD patients ( p = 0.01
and p = 0.00, respectively). The seroreactivity to 110-kDa
antigen was found to be significantly low in NUD patients
( p = 0.00). Although the difference did not reach statistical
significance, the frequency of 19.5-kDa bands was also found
to be higher in GCA patients than in NUD and PUD patients
(Figure 1).
Further analysis of the simultaneous combination of
immunoreactive bands at 19.5- and 35-kDa in the different
gastroduodenal diseases was undertaken; the four pheno-
types of antibody patterns are shown in Table 2. Logistic
regression analysis showed that the phenotype with the
Table 1 The frequency of Helicobacter pylori immunoreactive bands in patients with and without H. pylori infection, and in blood
donors with and without H. pylori infection by ELISA test and Helicoblot 2.1 immunoblotting
Immunoreactive
bands (kDa)
Patients Blood donor group
H. pylori-infected
(N = 89)
H. pylori-non-infected
(N = 17)
H. pylori-infected
(N = 20)
H. pylori-non-infected
(N = 10)
CIMb 62 (69.7) 1 (5.9) 17 (85) 1 (10)
19.5b 52 (58.4) 3 (17.6) 11 (55) 3 (30)
23 26 (29.2) 1 (5.9) 5 (25) 0 (0)
26 56 (62.9) 3 (17.6) 12 (60) 2 (20)
30 (UreA)b 71 (79.8) 2 (11.8) 15 (75) 3 (30)
35b 23 (25.8) 0 (0) 7 (35) 1 (10)
37b 32 (36.0)a 0 (0) 12 (60)a 2 (20)
55 55 (61.8) 0 (0) 15 (75) 1 (10)
66 87 (97.8) 17 (100) 20 (100) 10 (100)
75 40 (44.9) 0 (0) 10 (50) 1 (10)
78 29 (32.6) 0 (0) 6 (30) 1 (10)
85 64 (71.9) 0 (0) 11 (55) 2 (20)
89 (VacA)b 69 (77.5)a 1 (5.9) 11 (55)a 2 (20)
93 43 (48.3) 0 (0) 11 (55) 2 (20)
110 75 (84.3) 0 (0) 14 (70) 2 (20)
116 (CagA)b 87 (97.8) 9 (52.9) 20 (100) 2 (20)
CIM, current infection marker. Results are n (%).
a p < 0.05.
b Molecular weight of H. pylori antigen in the strip, according to the manufacturer.
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a band at 35-kDa was highly related to the outcome of GCA
( p = 0.007). The risk of phenotype 2 for GCA was statistically
significant with an odds ratio of 3.8, 95% confidence interval
of 1.4—10.3 (Table 3).
Discussion
Serological tests are non-invasive methods that have value
for the diagnosis of H. pylori infection because they are bothFigure 1 The frequency of Helicobacter pylori immunoreactive
difference among the gastroduodenal patient groups ( p < 0.05). NUD
carcinoma.simple and convenient.22 One of the serological tests, the
immunoblot assay, has the advantage of also being useful to
investigate possible relationships between disease presenta-
tion and the presence of specific H. pylori antigens.23 Pre-
vious studies have demonstrated that immunoblot
techniques can reveal multiple major antigens.5,24—26
Although the serum antibody response to H. pylori depends
on both the characteristics of the strain and the host
response, it can provide clues in predicting the severity of
H. pylori-associated diseases.bands in the gastroduodenal patients. *Statistically significant
, non-ulcer dyspepsia; PUD, peptic ulcer dyspepsia; GCA, gastric
Table 2 The prevalence of antibody patterns using the combination of 19.5-kDa and 35-kDa immunoreactive bands among
patients with gastroduodenal diseases
Disease Total number
of patients
No. (%) in the presence or absence of immunoreactive bands (kDa)
Phenotype 1 Phenotype 2 Phenotype 3 Phenotype 4
19.5 (+), 35 (+) 19.5 (+), 35 () 19.5 (), 35 (+) 19.5 (), 35 ()
Non-ulcer dyspepsia 44 7 (15.9) 16 (36.4) 1 (2.3) 20 (45.5)
Peptic ulcer dyspepsia 23 8 (34.8) 5 (21.7) 3 (13.0) 7 (30.4)
Gastric carcinoma 22 2 (9.1) 14 (63.6)a 2 (9.1) 4 (18.2)
a p < 0.05.
Table 3 The phenotype pattern of immunoreactive bands associated with gastric cancer
Phenotype Immunoreactive band Gastric cancer,
n (%) (N = 22)
Non-gastric cancer,
n (%) (N = 67)
p-Value OR (95% CI)
1 19.5 (+), 35 (+) 2 (9.1) 15 (22.4) 0.17 0.35 (<0.005—1.5)
2 19.5 (+), 35 () 14 (63.6) 21 (31.3) 0.007 3.8 (1.4—10.3) a
3 19.5 (), 35 (+) 2 (9.1) 4 (6.0) 0.61 1.6 (0.13—8.0)
4 19.5 (), 35 () 4 (18.2) 27 (40.3) 0.06 0.33 (0.11—1.04)
OR, odds ratio; CI, confidence interval.
a Statistically significant difference ( p < 0.05).
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pylori antibody profile in a Thai population in the northeast of
Thailand and its putative correlation with the clinical out-
come of gastroduodenal diseases. As well as the H. pylori
standard marker antigens, including 116-, 89-, 37-, 35-, 30-,
19.5-kDa, and CIM defined in themanufacturer’s instructions,
we also examined other immunoreactive antigens that can be
simultaneously detected on the strips, and used these immu-
noreactive bands for determining any correlation with the
clinical outcomes.
Our results show a variety of immunoreactive
patterns observed in both H. pylori-infected patients
and H. pylori-infected blood donors, with strong correla-
tions as in previous reports.5,25 It is not surprising that the
immunoreactive patterns from the H. pylori infections
were similar, because many antigens of H. pylori may
cross-react with other microorganisms. Moreover, the
blood donors may have been infected with H. pylori, but
were asymptomatic. There was no significant difference in
the immunoreactive bands found in the H. pylori-infected
patients and the H. pylori-infected blood donors, with the
exceptions of the antibody response against the 37-kDa
antigen (significantly higher in the H. pylori-infected blood
donors than the H. pylori-infected patients) and the 89-
kDa (VacA) antigen (significantly higher in the overall H.
pylori-infected patients than the H. pylori-infected blood
donors).
Although the difference did not reach statistical signifi-
cance, the frequency of 89-kDa antigen (VacA) was found to
be higher in the NUD than in the GCA and PUD groups. This
finding agrees with a previous study that demonstrated the
anti-VacA antibody was found more frequently in asympto-
matic control subjects than in ulcer and gastric cancer groups
in France.27
CagA and VacA appear to play a major role in pathogeni-
city.2,3 The association between the CagA and VacA antibo-dies and clinical outcomes has been reported.1,28,29 Both
VacA and CagA antigens have been shown to be significantly
related to gastroduodenal disease in Western coun-
tries,5,29,30 however no significant association has been found
in Asian countries.12,13,23,31,32 Previous studies have reported
that anti-VacA antigen is associated with the presence of
inflammation in the gastric body,33 and that the anti-CagA
antigen is highly associated with gastric cancer and peptic
ulcer.34,35 Our findings agree with several Asian studies and a
study in a United States population, in which no significant
association was found between those antigens and the devel-
opment of gastroduodenal diseases.12,13,23,31,32,36 A previous
study showed that the antibodies to CagA and 35-kDa antigen
were higher in patients with peptic ulcers, especially when
they had spent their childhood in Africa.16 Therefore it might
be that not only VacA and CagA, but also the other proteins
increase the virulence of disease.
We confirm that VacA andCagA antibodieswere not useful
to differentiate clinical outcomes in a Thai population.
Strong associations between the presence of anti-CagA
and the cagA-positive and vacAs1 H. pylori genotypes have
been observed.37 The high prevalences of antibodies to VacA
and CagA found in this study correspond to the occurrences
of the vacA and cagA genes in a previous report.10 The
discordance of these reports may be due to geographic
variations in H. pylori strains or to the host immune
response.
We also found that the simultaneous presence of antibody
to the 19.5-kDa antigen and the absence of antibody to the
35-kDa antigen of H. pylori infection were significantly
associated with an increased risk of gastric cancer. This
finding agrees with those of previous reports.17,23 In addi-
tion, we confirm the previous observations regarding a
relationship between the 35-kDa antigen elicited antibody
and peptic ulcer disease.5,38 However, several immunoreac-
tive bands have been reported to be associated with the
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the 19.5-, 33- and 136-kDa (CagA) antigen have been shown
to indicate a markedly increased probability of more severe
gastroduodenal disease.39 The 33-kDa antigen may be that
identified as the 34- or 35-kDa antigen in previous stu-
dies17,23 and in this study. The 34-kDa antigen has recently
been identified as OipA, a protein that enhances interleukin-
8 production in the host, resulting in cell inflammation and
apoptosis.40
The 19.5-kDa antigen has been identified as urease
accessory protein, UreE, encoded by the ureE gene.41
The role of UreE remains unclear, although it has been
hypothesized to provide the active site of urease with
nickel ion and to be involved in urease maturation.42—44
Several studies have suggested that the 35-kDa antigen
may play a role in disease pathogenesis and that the 37-kDa
antigen of H. pylori may be protective. The presence of
unidentified factors or antigens that have disease associa-
tion may exist.16,17,23
Other immunoreactive protein bands besides the HB 2.1
marker bands were observed. A low frequency of antibody to
23- and 85-kDa antigens was significantly associated with
PUD. The 85-kDa antigen, which may be identical to the 82-
kDa antigen reported in a previous study, was identified as
putative cytotoxin.3,45 However, the 22-kDa antigen, which
may be 23-kDa in this study, remains to be identified, and
proper identification is required to elucidate its nature and
role. Future studies are needed to investigate whether the
absence of these immunoreactive bands is due to the expres-
sion being switched off in response to the gastric environ-
ment or whether patients who subsequently develop
gastroduodenal diseases are not responding to these anti-
gens.
Our results show a high prevalence of 66-kDa antigen in all
H. pylori-infected and non-infected patients and donors. The
66-kDa antigen has been identified as UreB.46,47 Cross-reac-
tivity with antigens of other bacterial species has been
shown.25 The 55-kDa antigen, probably a heat shock protein
54-kDa (H. pylori 54-kDa), was also found to be highly pre-
valent in both infected patients and donors, and has been
reported to be increasingly synthesized in response to many
environmental stresses.48 It has been suggested that heat
shock proteins might be involved in the pathogenesis of H.
pylori-related diseases through the induction of an autoim-
mune response and could be a potential component of a
future vaccine.49
In this study, seroreactivity to 66-, 110-, and 116-kDa
(CagA) antigens were found to be the most prevalent in both
H. pylori-infected patients and H. pylori-infected blood
donors. This indicates that these antigens are highly immu-
nogenic. However, seroreactivity to the 35-, 37-, 55-, 75-, 78-
, 85-, 93-, and 110-kDa antigens was not found in the H.
pylori-non-infected patients, therefore these immunoreac-
tive bands should be specific and may be useful for the
diagnosis of H. pylori infection, and some bands were found
more frequently, as in previous reports.3,25
Other research groups have frequently found different
seroreactive bands for H. pylori infection, such as seror-
eactivity to the 130-, 93-, 75-, and 67-kDa antigens,50 or to
the 110/120-kDa and/or two of five low molecular mass
proteins (26-, 29-, 30-, 31-, and 33-kDa, in any combina-
tion),25 and some investigators have found that the 26.5-,30-, and 116-kDa antigens are the most prevalent.14—16,25,51
In another report, the 110- and 63-kDa antigens on IgG
immunoblot and an 89-kDa antigen on IgA immunoblot were
found to be the most specific for H. pylori infection.52
However, Lepper et al.53 have suggested that the detection
of H. pylori infection varies because of the use of different
criteria for interpreting immunoblot results in H. pylori
infection.
As well as the use of different criteria for the interpreta-
tion of H. pylori infection, results also depend on the H.
pylori strain used for antigen preparation and the polymorph-
ism of the antibody response to H. pylori.5,24—26 Our study
used the HB 2.1 strip, which contained different H. pylori
antigens, and the criteria for a positive H. pylori infection
were as per the manufacturer’s instructions. The other
immunoreactive bands were assessed using a calibrating
curve. Therefore, prior to the determination of which immu-
noreactive bands are found, we suggest that the H. pylori
infection should be determined first and that the molecular
weight proteins should be estimated and compared to those
of other investigators.
In conclusion, we confirm that the universal antibodies to
CagA and VacA are not useful for differentiating clinical
outcome among gastroduodenal disease patients in the
northeast of Thailand. Using an immunoblot analysis,
the simultaneous presence of the 19.5-kDa antigen and the
absence of 35-kDa antigen may be useful as an indirect
marker for H. pylori-infected patients at high risk of gastric
cancer. The presence of 35-kDa antigen is associated with
peptic ulcer and that of 37-kDa antigen is associated with
non-ulcer dyspepsia. Although the cause of gastroduodenal
disease, especially gastric cancer, with H. pylori infection is
multi-factorial, further studies are needed to identify and
characterize the pathogenic roles of the 19.5-, 35-, and 37-
kDa antigens of H. pylori, which may serve as a useful tool in
reducing the risk of gastroduodenal diseases. In addition, H.
pylori-infected patients who have the presence of the 19.5-
kDa antigen and the absence of 35-kDa antigen should be
followed up for the possible progression of gastric cancer.
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